Therapeutic potentials for glial cell line-derived neurotrophic factor (GDNF) based upon pharmacological activities in the CNS

Reviews in the Neurosciences

Volumn 7, Issue 3, 1996, Pages 165-176

  Lapchak, Paul A ^a  

^a AMGEN INC   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cholinergic neurons; Cognitive dysfunction; Dopamine neurons; Glial cells; Motor neurons; Neurotrophic factor; Parkinson's disease

Indexed keywords

NEUROTROPHIC FACTOR;

AMYOTROPHIC LATERAL SCLEROSIS; CELL LINE; DEGENERATIVE DISEASE; DEMENTIA; DOPAMINERGIC NERVE CELL; GLIA CELL; HUMAN; MOTONEURON; MOTOR NEURON DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0029860408     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.1996.7.3.165     Document Type: Review

References (48)

1. Adams RA, Victor M. Degenerative diseases of the nervous system. In: Principles of Neurology. McGraw Hill, 1993.
2. Arenas E, Trupp M, Akerud P, Ibanez CF. GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo. Neuron 1995; 5: 1465-1473.
3. Blum M, Weickert CS. GDNF mRNA expression in normal postnatal development, aging and in weaver mutant mice. Neurobiol Aging 1995; 16: 925-929.
4. Bowenkamp KE, Hoffman AF, Gerhardt GA, Henry MA, Biddle PT, Hoffer BJ, Granholm ACE. Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 1995; 355: 479-489.
5. Bowenkamp KE, David D, Lapchak PA, Henry MA, Granholm AC, Hoffer BJ, Mahalik TJ. 6-Hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. Exp Brain Res 1996; in press.
6. Cass WA, Dugan MT. GDNF protects against methamphetamine-induced reductions in striatal dopamine release and content in rats. ASNT 1996; in press.
7. Collins F, Lapchak PA. Morphological and functional effects of GDNF in rodents and primates. Soc Neurosci 1995; 21: 493.
8. Gash DM, Zhang Z, Cass WA, Ovadia A, Simmerman L, Russell D, Martin D, Collins FC, Hoffer BJ, Gerhardt GA. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 1995; 363: 345-358.
9. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins FC, Hoffer BJ, Gerhardt GA. Functional recovery in GDNF-treated Parkinsonian monkeys. Nature 1996; 380: 252-255.
10. + overflow of dopamine in the striatum. Soc Neurosci 1995; 21: 225.5.
11. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simpson LC, Moffet B, Vandlen RA, Koliatsos VE, Rosenthal A. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Nature 1995; 266: 1062-1064.
12. Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell derived neurotrophic factor reversed toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182: 107-111.
13. Hou JGG, Lin LFH, Mytilineou C. Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 1996; 66: 74-82.
14. Hudson J, van Horne CG, Stromberg I, Brock S, Clayton J, Masserano J, Hoffer BJ, Gerhardt GA. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993; 626: 167-174.
15. Humpel C, Hoffer B, Stromberg I, Bektesh S, Collins F, Olson L. Neurons of the hippocampal formation express glial cell line-derived neurotrophic factor messenger RNA in response to kainate-induced excitation. Neuroscience 1994; 59: 791-795.
16. Jenner P. The rationale for the use of dopamine agonists in Parkinson's disease. Neurology 1995; 45: S6-S12.
17. Kalivas PW, Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 1991; 16: 223-244.
18. Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995; 672: 101-111.
19. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 1984; 292: 390-394.
20. Lapchak PA, Araujo DM, Hefti F. Neurotrophins in the CNS. Rev Neurosci 1992; 3: 1-10.
21. Lapchak PA. Therapeutic potential for nerve growth factor in Alzheimer's disease: insights from pharmacological studies using lesioned central cholinergic neurons. Rev Neurosci 1992; 3: 109-119.
22. 123I-GDNF in the rat and primate CNS following icv injections: correlation with the behavioral and pharmacological activities of icv administered GDNF in Parkinson's disease models. ASNT 1996; in press.
23. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden D, Franchowiak RSJ. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteers and in patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-1298.
24. Li L, Wu W, Lin LFH, Lei M, Oppenheim RW, Houenou LJ. Rescue of adult motoneurons from injury-induced cell death by GDNF. PNAS 1995; 92: 9771-9775.
25. Lin L-F, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-1132.
26. 3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988; 156: 331-340.
27. Marsden CD, Parkes JD, Quinn N. Fluctuations of disability in Parkinson's disease - Clinical aspects. In: Marsden CD, Fahn S, eds. Movement Disorders. London: Butterworths Scientific, 1982; 96-122.
28. Martin D, Miller G, Rosendahl M, Russell DA. Potent inhibitory effects of GDNF against kainic acid mediated seizures in rats. Brain Res 1995; 683: 172-178.
29. Martin D, Miller G, Fischer N, Dix D, Cullen T. Glial derived neurotrophic factor: the lateral cerebral ventricle is an effective site of administration for stimulation of the nigrostriatal system. Eur J Neurosci 1996; in press.
30. Mount HTJ, Dean DO, Alberch J, Dreyfus CF, Black IB. GDNF promotes the survival and morphologic differentiation of Purkinje cells. PNAS 1995; 92: 9092-9096.
31. Pare D, Curro'Dossi R, Steriade M. Neuronal basis of the parkinsonian resting tremor: a hypothesis and its implications for treatment. Neuroscience 1990; 35: 217-226.
32. Oppenheim RW, Houenou LJ, Johnson JE, Lin LFH, Li L, Lo AC, Newsome AL, Prevette DM, Wang S. Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF. Nature 1995; 363: 344-346.
33. Sauer H, Rosenblad C, Bjorklund A. Glial cell line-derived neurotrophic factor but not transforming growth factor B3 prevents delayed degeneration of nigral neurons following striatal 6-hydroxydopamine lesions. PNAS 1995; 92: 8935-8939.
34. Scharr DG, Sieber BA, Dreyfus CF, Black I. Regional and cell-specific expression of GDNF in rat brain. Exp Neurol 1993; 24: 368-371.
35. Schmidt-Kastner R, Tomac A, Hoffer B, Bektesh S, Rosenzweig B, Olson L. Glial cell-line derived neurotrophic factor (GDNF) mRNA upregulation in striatum and cortical areas after pilocarpine-induced status epilepticus in rats. Mol Brain Res 1994; 26: 325-330.
36. Shults CW, Shin C, Ernesto C, Martin D. Effects of intrastriatal injections of glial cell line-derived neurotrophic factor (GDNF) in rats. Exp Neurol 1996; in press.
37. Smith RD, Zhang Z, Kurlan R, McDermott M, Gash DM. Developing a stable bilateral model of Parkinsonism in rhesus monkey. Neuroscience 1993; 52: 7-16.
38. Springer JE, Seeburger JL, He J, Gabrea A, Blankenhorn EP, Bergman LW. cDNA sequence and differential mRNA regulation of two forms of glial cell line-derived neurotrophic factor in Schwann cells and rat skeletal muscle. Exp Neurol 1995; 131: 47-52.
39. Stromberg I, Bjorklund L, Johansson M, Tomac A, Collins F, Olson L, Hoffer BJ, Humpel C. Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 1993; 124: 401-412.
40. Suter-Crazzolara C, Unsicker K. GDNF is expressed in two forms in many tissues outside the CNS. NeuroReport 1994; 5: 2486-2488.
41. Tomac A, Widenfalk J, Lin LFH, Kohno T, Ebendal T, Hoffer BJ, Olson L. Retrograde axonal transport of GDNF in the adult nigrostriatal system suggests a trophic role in the adult. PNAS 1995; 92: 8274-8278.
42. Tomac A, Lindqvist E, Lin LFH, Ogren SO, Young D, Hoffer BJ, Olson L. Protection and repair of nigrostriatal dopaminergic neurons by GDNF in vivo. Nature 1995; 373: 335-339.
43. Torack RM, Morris JC. Tyrosine hydroxylase-like (TH) immunoreactivity in Parkinson's disease and Alzheimer's disease. J Neural Transm 1992; 4: 165-171.
44. Trupp M, Ryden M, Jornvall H, Funakoshi H, Timmusk T, Arenas E, Ibanez CF. Peripheral expression and biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell Biol 1995; 130: 137-148.
45. Wichmann T, Vitek JL, DeLong MR. Parkinson's disease and the basal ganglia: lessons from the laboratory and from neurosurgery. Neuroscientist 1995; 1: 236-244.
46. Williams LR, Inouye G, Cummins V, Pelleymounter MA. GDNF sustains axotomized basal forebrain cholinergic neurons in vivo: dose-response comparison to NGF and BDNF. JPET 1996; in press.
47. Yan Q, Matheson C, Lopez OT. In vivo neurotrophic effects of r-metHuGDNF on neonatal and adult facial motor neurons. Nature 1995; 373: 341-344.
48. Zurn AD, Baetge EE, Hammang JP, Tan SA, Aebischer P. Glial cell line-derived neurotrophic factor (GDNF), a new neurotrophic factor for motoneurons. NeuroReport 1994; 6: 113-118.